Epidemiology and early predictors of Fabry nephropathy: evaluation of long-term outcomes from a national Fabry centre
Fahmida Mannan(Manchester Academic Health Science Centre), Ana Jovanović(Manchester Academic Health Science Centre), Éamon P McCarron(Northern General Hospital), Ryan Wiltshire(Salford Royal NHS Foundation Trust), Reena Sharma(Salford Royal NHS Foundation Trust), Rajkumar Chinnadurai(University of Manchester), Philip A. Kalra, Karolina M. Stępień(Medical University of Warsaw), Jan Hansel(University of Manchester), Gisela Wilcox(Salford Royal NHS Foundation Trust)
Cited by 4
Related Papers
Chronic Kidney Disease and Coronary Artery Disease
|Journal of the American College of Cardiology|2019|716
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
|Kidney International|2016|474
Statin-induced myopathies
|Pharmacological Reports|2011|206